EssilorLuxottica (OTCMKTS:ESLOY) & Flora Growth (NASDAQ:FLGC) Head-To-Head Analysis

EssilorLuxottica (OTCMKTS:ESLOY) and Flora Growth (NASDAQ:FLGC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Profitability

This table compares EssilorLuxottica and Flora Growth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EssilorLuxottica	N/A	N/A	N/A
Flora Growth	-24.86%	-261.57%	-48.06%

Institutional and Insider Ownership

0.0% of EssilorLuxottica shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 12.6% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares EssilorLuxottica and Flora Growth”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EssilorLuxottica	$28.69 billion	5.02	$2.55 billion	N/A	N/A
Flora Growth	$59.51 million	0.21	-$15.91 million	($34.38)	-0.64

EssilorLuxottica has higher revenue and earnings than Flora Growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for EssilorLuxottica and Flora Growth, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EssilorLuxottica	0	1	0	0	2.00
Flora Growth	0	0	2	0	3.00

Flora Growth has a consensus price target of $93.00, indicating a potential upside of 325.05%. Given Flora Growth’s stronger consensus rating and higher possible upside, analysts plainly believe Flora Growth is more favorable than EssilorLuxottica.

Risk & Volatility

EssilorLuxottica has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500.

About EssilorLuxottica

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.